Effect of Clozaril (Clozapine) on White Blood Cell Count

Hematological Effects of Clozapine

Clozapine can cause potentially fatal agranulocytosis in approximately 1% of patients, requiring mandatory and rigorous WBC monitoring throughout treatment 1, 2
Agranulocytosis, a severe form of neutropenia with ANC less than 500/μL, occurs in approximately 1% of patients and is potentially fatal 2
Youth may have higher rates of agranulocytosis compared to adults 1

Before starting therapy, baseline WBC must be at least 3,500/mm³, with no evidence of myeloproliferative disorder or history of agranulocytosis, and avoid concurrent medications that can lower blood cell counts 1, 2
Weekly blood cell counts for the first 6 months, every 2 weeks for the next 6 months, and monthly after 12 months of continuous therapy, with continued monitoring for 4 weeks after medication is stopped 2

If WBC drops below 2,000/mm³ or ANC below 1,000/mm³, stop medication immediately, monitor for infection with daily blood counts, and consider hematological consultation 2
If WBC is 2,000-3,000/mm³ or ANC is 1,000-1,500/mm³, stop medication immediately, monitor for infection with daily blood counts, and may resume when WBC >3,000/mm³ and ANC >1,500/mm³ with no signs of infection 1, 2
If WBC is 3,000-3,500/mm³ or drops by 3,000/mm³ over 1-3 weeks, repeat count, and if WBC remains 3,000-3,500/mm³ and ANC >1,500/mm³, monitor biweekly 1, 2

Failing to obtain baseline WBC counts before initiating treatment, not adhering to the required monitoring schedule, ignoring small drops in WBC or ANC, and continuing clozapine when WBC/ANC values fall below critical thresholds 2